Embargo Policy

The embargo on all abstracts accepted to the 2019 Genitourinary Cancers Symposium will lift at 5:00 p.m. ET on Monday, February 11, 2019. An embargoed presscast (virtual press briefing held via teleconference and webinar) will be held at 12:00 noon ET on February 11 for credentialed media.

Media Policies

Attend the Meeting in Person/Participate in the Presscast

Media registration for the 2019 Genitourinary Cancers Symposium is now open. At this time, you can visit ASCO's Media Headquarters to apply for media credentials,* register to attend an upcoming meeting, access embargoed meeting information, and locate presscast dial-in information. For questions about how to navigate the site, please contact ASCO Media Registration.

*If you attended the 2018 ASCO Annual Meeting or covered the meeting remotely, you have already been credentialed by ASCO and will have access to the embargoed meeting information and the presscast. You only have to register if you want to attend the Genitourinary Cancers Symposium in person in San Francisco.

Access Embargoed Information

Embargoed meeting information will be made available to credentialed media through ASCO's Media Headquarters. Once your media credentials are approved, you will receive email notifications when embargoed information has been posted.

Press Releases

Coming soon!

Meet the News Planning Team

Coming soon!

Meeting Information

Past Meetings

2018 Genitourinary Cancers Symposium:

  • 2018 Symposium Highlights Notable Research Advances in Genitourinary Cancers
    SAN FRANCISCO - Eight noteworthy studies exploring key research in the treatment of genitourinary cancers will be presented at the 2018 Genitourinary Cancers Symposium, taking place February 8-10 at the Moscone West Building in San Francisco, California. Read the full release.
  • Adding Immunotherapy to Standard Treatment Slows Growth of Advanced Kidney Cancer, With Fewer Side Effects
    ALEXANDRIA, Va. – In a phase III clinical trial of people with previously untreated metastatic renal cell cancer (mRCC), combining immunotherapy atezolizumab with targeted therapy bevacizumab delayed cancer growth by about three months longer than sunitinib, another targeted therapy. Read the full release.
  • New Model Predicts Survival for People With Bladder Cancer Receiving Immunotherapy
    ALEXANDRIA, Va. – Researchers have developed a model to predict overall survival for people with advanced urothelial cancers treated with the immune checkpoint inhibitor atezolizumab. Read the full release.
  • Chemotherapy Added to Hormone Therapy for Prostate Cancer Improves Quality of Life
    ALEXANDRIA, Va. – A new analysis of the ongoing STAMPEDE clinical trial found that adding the chemotherapy drug docetaxel to hormone therapy for advanced prostate cancer improves quality of life and lowers the need for subsequent therapy. Docetaxel was also found to be cost-effective. Read the full release.
  • Apalutamide Delays Prostate Cancer Metastases by More Than Two Years
    ALEXANDRIA, Va. – Findings from the phase III placebo-controlled SPARTAN trial suggest that apalutamide is an effective treatment for men with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk for developing metastatic disease, and for whom no approved treatments exist. Read the full release.
  • Upcoming Symposium to Feature New Insights for Management of Prostate, Bladder, Kidney Cancers
    ALEXANDRIA, Va. – Co-sponsors of the 2018 Genitourinary Cancers Symposium announced today four abstracts to be highlighted in the meeting’s official Press Program. Researchers will present the findings of these studies in an embargoed presscast for reporters, taking place Monday, February 5, 2018, from 12:00 noon – 1:30 p.m. ET. Read the full release.

Media Resources

How Can We Help You?